Compugen. has filed a patent for PVRIG polypeptides and their uses. The patent includes a method for screening inhibitors of the binding association between PVRIG polypeptide and PVLR2. This method involves providing a surface with specific proteins and determining binding interactions. GlobalData’s report on Compugen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Compugen, Personalized cancer vaccines was a key innovation area identified from patents. Compugen's grant share as of January 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
Screening method for inhibitors of pvrig-pvlr2 binding
The patent application (Publication Number: US20240025973A1) describes methods for screening inhibitors of the binding association between PVRIG and PVLR2, two proteins involved in immune responses. The first method involves using a surface with ligand proteins, while the second method utilizes cells expressing the proteins. Additionally, a test solution with labeled proteins can be used to detect binding inhibition. The patent also covers methods for treating disorders related to PVRIG-PVLR2 interaction by administering a stimulator of PVRIG to modulate immune responses, including T cell activation and cytokine secretion.
Furthermore, the patent application includes compositions comprising isolated PVRIG polypeptides and fusion polypeptides with various fusion partner moieties. These compositions can be used to suppress T cell activation in patients with immune disorders such as autoimmune diseases and organ transplant rejection. The fusion partner moieties include human IgG Fc domains, human serum albumin, and polyethylene glycol, among others. The compositions can be administered with a pharmaceutically acceptable carrier to achieve the desired therapeutic effects, highlighting the potential applications of these methods and compositions in immune-related disorders.
To know more about GlobalData’s detailed insights on Compugen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
